Biolinq
San Diego, US · Delaware corporation · 8 known investors
Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
Founders & leadership
JT
Jared TangneyinCo-Founder, President & CTO
RY
Richard YangNamed on SEC filing
EK
Edward KliphuisNamed on SEC filing
Board
DB
LG
Investors · 8
Reported raises · per SEC filings
Form D private placements$247.4M disclosed across 8 rounds · 2016–2025
▶$90MraisedMar 2025 · 45 investors · BiotechnologyRule 506(b)
▶$90MraisedMar 2025 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CHRIS DIMITROPOULOSDirector
- DAVID BERRYDirector
- DEREK RAPPDirector
- ZINA AFFAS BESSEDirector
- RICHARD YANGExecutive Officer, Director
- THAD JOHNSONDirector
- JARED TANGNEYExecutive Officer
- DAN BRADBURYDirector
- DAVID ARIDAExecutive Officer
- Offering amount
- $100M
- Amount sold
- $90M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$59.1MraisedSep 2024 · 43 investors · BiotechnologyRule 506(b)
▶$59.1MraisedSep 2024 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DEREK RAPPDirector
- THAD JOHNSONDirector
- CHRIS DIMITROPOULOSDirector
- DAVID BERRYDirector
- JARED TANGNEYExecutive Officer
- DAN BRADBURYDirector
- RICHARD YANGExecutive Officer, Director
- DAVID ARIDAExecutive Officer
- ZINA AFFAS BESSEDirector
- Offering amount
- $59.1M
- Amount sold
- $59.1M
- Sales commissions
- $550K
- Placement agents
- J.P. Morgan Securities LLC
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$77.9MraisedJun 2022 · 62 investors · BiotechnologyRule 506(b)
▶$77.9MraisedJun 2022 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jared TangneyExecutive Officer
- Dan BradburyDirector
- Thad JohnsonDirector
- Nancy HongDirector
- Richard YangExecutive Officer, Director
- Offering amount
- $105.6M
- Amount sold
- $77.9M
- Sales commissions
- $1.6M
- Proceeds to insiders
- $35K
- Placement agents
- Covington Associates, LLC
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedMar 2021 · 21 investors · BiotechnologyRule 506(b)
▶$5.2MraisedMar 2021 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel BradburyDirector
- Richard YangExecutive Officer, Director
- Edward KliphuisDirector
- Lana GhanemDirector
- Jared TangneyExecutive Officer, Director, Promoter
- Offering amount
- $6M
- Amount sold
- $5.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.6MraisedJul 2020 · 17 investors · BiotechnologyRule 506(b)
▶$3.6MraisedJul 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lana GhanemDirector
- Jared TangneyExecutive Officer, Director, Promoter
- Joshua WindmillerExecutive Officer, Director, Promoter
- Daniel BradburyDirector
- Edward KliphuisDirector
- Offering amount
- $10M
- Amount sold
- $3.6M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2019 · 9 investors · BiotechnologyRule 506(b)
▶$3MraisedMar 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward KliphuisDirector
- Daniel BradburyDirector
- Lana GhanemDirector
- Joshua WindmillerExecutive Officer, Director, Promoter
- Jared TangneyExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedNov 2017 · 17 investors · BiotechnologyRule 506(b)
▶$8.1MraisedNov 2017 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lana GhanemDirector
- Edward KliphuisDirector
- Joshua WindmillerExecutive Officer, Director, Promoter
- Jared TangneyExecutive Officer, Director, Promoter
- Offering amount
- $13.1M
- Amount sold
- $8.1M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$450KraisedSep 2016 · 5 investors · BiotechnologyRule 506(b)
▶$450KraisedSep 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jared TangneyExecutive Officer, Director, Promoter
- Joshua WindmillerExecutive Officer, Director, Promoter
- Offering amount
- $750K
- Amount sold
- $450K
- Minimum investment
- $50K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Biolinq went on to found or lead other companies.
In the news
Frequently asked questions
- What does Biolinq do?
- Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
- Who founded Biolinq?
- Biolinq was founded by Jared Tangney.
- Who are Biolinq's investors?
- Biolinq's investors include Alpha Wave Global, Beyond Capital, BioBrit, JDRF T1D Fund, Aphelion Capital, Hikma Ventures, LifeSci Venture Partners, RiverVest Venture Partners.
- How much funding has Biolinq raised?
- Biolinq has disclosed $247.4M raised across 8 rounds.
- Where is Biolinq headquartered?
- Biolinq is headquartered in San Diego, US.